Lantern Pharma Inc reports results for the quarter ended in September 30 - Earnings Summary

Lantern Pharma

08/11/2024 04:25

* Lantern Pharma Inc  LTRN.OQ  reported a quarterly adjusted
loss
of 42 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -29 cents.  The lone analyst forecast for the quarter was
for a loss of 56 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Lantern Pharma Inc's reported EPS for the quarter was a
loss
of 42 cents​.
    * The company reported a quarterly loss of $4.51 million.
    * Lantern Pharma Inc shares had fallen by 9.8% this
quarter and
lost 22.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Lantern Pharma
Inc is 22.00 
This summary was machine generated from LSEG data November 8 at
04:25 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.56          -0.42          Beat
 Jun. 30 2024      -0.55          -0.46          Beat
 Mar. 31 2024      -0.43          -0.51          Missed
 Dec. 31 2023      -0.40          -0.39          Beat